Skin Diseases, Infectious Clinical Trial
Official title:
An Evaluation of the Safety, Efficacy and Pharmacokinetics of Daptomycin in Pediatric Subjects Aged One to Seventeen Years With Complicated Skin and Skin Structure Infections Caused by Gram-Positive Pathogens
This is a multi-center, evaluator-blinded, randomized, comparative study designed to assess the safety, efficacy, and pharmacokinetics (PK) of daptomycin in pediatric subjects ages 1 to 17 years, inclusive, with complicated skin and skin structure infections (cSSSI) caused by Gram-positive pathogens.
This is a multi-center, evaluator-blinded, randomized, comparative study designed to assess the safety, efficacy, and PK of daptomycin in pediatric participants ages 1 to 17 years, inclusive, with cSSSI caused by Gram-positive pathogens. Participants will be enrolled into age groups and given age-dependent doses over a period of up to 14 days. Participants will be stratified by age group to receive either daptomycin or SOC (recommended as vancomycin, clindamycin or semisynthetic penicillin) in a ratio of 2:1, respectively. Participants may continue on oral therapy following completion of IV study drug administration and provided that the participant meets all criteria for conversion to oral therapy, including clear clinical improvement and availability of an oral agent to which the pathogen is susceptible. The choice of oral therapy will be left to the discretion of the Investigator. February 11, 2015 released from post marketing requirement to include subjects aged 3 months - < 1 year. Ref ID: 3701325 ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00746109 -
Study of Wound Packing After Superficial Skin Abscess Drainage
|
Phase 4 | |
Completed |
NCT00210899 -
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
|
Phase 3 | |
Completed |
NCT00761215 -
Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections
|
Phase 2 | |
Completed |
NCT00228982 -
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
|
Phase 3 | |
Completed |
NCT01967225 -
Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections
|
Phase 3 | |
Withdrawn |
NCT00990392 -
Topical Antibiotics for Prevention of Intensive Care Unit (ICU) Central Line Infections
|
N/A | |
Completed |
NCT00228410 -
Study Comparing Tigecycline and Vancomycin With Aztreonam in Complicated Skin and Skin Structure Infections
|
Phase 3 | |
Completed |
NCT05608382 -
Effect of an Antiseptic Solution on the Skin Microbiome
|
N/A | |
Completed |
NCT03487549 -
Cantharidin and Occlusion in Verruca Epithelium
|
Phase 2 | |
Completed |
NCT02276482 -
Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)
|
Phase 3 | |
Completed |
NCT00198679 -
Effect of Chlorhexidine Skin Cleansing on Skin Flora
|
Phase 4 | |
Completed |
NCT03981822 -
A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts
|
Phase 2 | |
Completed |
NCT00488761 -
Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cSSSI
|
Phase 4 | |
Completed |
NCT00679302 -
Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management
|
Phase 4 | |
Completed |
NCT00257036 -
A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Mild to Moderate Infections of the Skin and the Supportive Layers Beneath the Skin
|
Phase 2/Phase 3 | |
Completed |
NCT04485676 -
Dalbavancin in Real Clinical Practice in Spain
|
||
Completed |
NCT00785200 -
MRSA Colonization and Control in the Dallas County Jail
|
N/A | |
Completed |
NCT00257062 -
A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Uncomplicated Infections of the Skin and the Supportive Layers Beneath the Skin
|
Phase 3 | |
Completed |
NCT02582203 -
Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA
|
Phase 4 | |
Completed |
NCT00388310 -
Effective Antibiotic Treatment of MRSA
|
N/A |